Literature DB >> 8559633

Bacteriology and beta-lactamase activity in ear aspirates of acute otitis media that failed amoxicillin therapy.

I Brook1, P Yocum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8559633

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  7 in total

Review 1.  Management of acute otitis media in the 1990s: the decade of resistant pneumococcus.

Authors:  S L Block
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  "It Takes a Village": Mechanisms Underlying Antimicrobial Recalcitrance of Polymicrobial Biofilms.

Authors:  Giulia Orazi; George A O'Toole
Journal:  J Bacteriol       Date:  2019-12-06       Impact factor: 3.490

3.  Optimal dose of amoxicillin in treatment of otitis media caused by a penicillin-resistant pneumococcus strain in the gerbil model.

Authors:  Araceli Parra; Carmen Ponte; Carlos Cenjor; Gloria García-Calvo; María José Giménez; Lorenzo Aguilar; Francisco Soriano
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

4.  β-Lactamase-Producing Bacteria in Upper Respiratory Tract Infections.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

5.  Relationship with original pathogen in recurrence of acute otitis media after completion of amoxicillin/clavulanate: bacterial relapse or new pathogen.

Authors:  Ravinder Kaur; Janet R Casey; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

6.  Multicenter, randomized, double-blind comparison of erythromycin estolate versus amoxicillin for the treatment of acute otitis media in children. AOM Study Group.

Authors:  H Scholz; R Noack
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-07       Impact factor: 3.267

Review 7.  The role of beta-lactamase-producing-bacteria in mixed infections.

Authors:  Itzhak Brook
Journal:  BMC Infect Dis       Date:  2009-12-14       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.